New shot every 12 weeks aims to control advanced prostate cancer

NCT ID NCT04729114

Recruiting now Disease control Sponsor: Astellas Pharma Global Development, Inc. Source: ClinicalTrials.gov ↗

First seen Sep 30, 2025 · Last updated May 16, 2026 · Updated 33 times

Summary

This study tests a new medicine called PRL-02 depot, given as a shot into the muscle every 12 weeks, to lower testosterone in men with advanced prostate cancer. The goal is to find a safe dose and see if it works alone or with another drug, enzalutamide. About 174 men whose cancer has returned or not responded to prior treatment will take part. The study checks safety, side effects, and how well the drug controls the cancer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Arizona Urology Specialists
WITHDRAWN

Tucson, Arizona, 85715, United States
Carolina Urologic Research Center
RECRUITING

Myrtle Beach, South Carolina, 29572, United States
Chesapeake Urology
RECRUITING

Towson, Maryland, 21204, United States
Duke Cancer Center
RECRUITING

Durham, North Carolina, 27710, United States
First Urology
RECRUITING

Jeffersonville, Indiana, 47130, United States
Florida Urology Partners
WITHDRAWN

Tampa, Florida, 33609, United States
Fort Wayne Medical Oncology and Hematology, Inc.
WITHDRAWN

Fort Wayne, Indiana, 46804, United States
Garden Sate Urology
WITHDRAWN

Morristown, New Jersey, 07960, United States
Helios Clinical Research, LLC
WITHDRAWN

Middleburg Heights, Ohio, 44130, United States
Houston Metro Urology
RECRUITING

Houston, Texas, 77027, United States
Los Angeles Cancer Network
RECRUITING

Anaheim, California, 92801, United States
MidLantic Urology
RECRUITING

Bala-Cynwyd, Pennsylvania, 19004, United States
National Cancer Institute
WITHDRAWN

Bethesda, Maryland, 20892, United States
New Mexico Oncology Hematology Consultants Ltd
RECRUITING

Albuquerque, New Mexico, 87109, United States
Northwest Medical Specialties
RECRUITING

Tacoma, Washington, 98405, United States
Oncology Consultants
WITHDRAWN

Houston, Texas, 77030, United States
Pan American Center for Oncology Trials, LLC
RECRUITING

San Juan, Rio Piedras, 00935, Puerto Rico
Providence Medical Group Oncology Santa Rosa
RECRUITING

Santa Rosa, California, 95403, United States
Toledo Clinical Cancer Center
WITHDRAWN

Toledo, Ohio, 43623, United States
University of Virginia Cancer Center
RECRUITING

Charlottesville, Virginia, 22908, United States
Urology Associates PC
RECRUITING

Nashville, Tennessee, 37209, United States
Urology Clinics of North Texas
RECRUITING

Dallas, Texas, 75231, United States
Urology San Antonio
WITHDRAWN

San Antonio, Texas, 78229, United States
Wichita Urology Group
RECRUITING

Wichita, Kansas, 67226, United States
XCancer Center Omaha/Urology Cancer Center
COMPLETED

Omaha, Nebraska, 68130, United States

Conditions

Explore the condition pages connected to this study.

METASTATIC CASTRATION-RESISTANT PROSTATE CANCER METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER PROSTATE CANCER